Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud

Background Genetic variations of some driver genes in non-small cell lung cancer (NSCLC) had shown potential impact on immune microenvironment and associated with response or resistance to programmed cell death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an exploratory analysis t...

Full description

Bibliographic Details
Main Authors: Yi-Long Wu, De-Hua Wu, Si-Cong Ma, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Zhong-Yi Dong
Format: Article
Language:English
Published: BMJ Publishing Group 2020-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000381.full

Internet

https://jitc.bmj.com/content/8/1/e000381.full

Similar Items